Welcure Drugs & Pharma plans to invest ₹80 crore in agro pharma research lab
Welcure Drugs & Pharmaceuticals plans to invest about ₹80 crore in setting up a modern Current Good Manufacturing Practice (cGMP) (regulatory standard) research laboratory dedicated for agro pharma research.
The size of the project is estimated to be around ₹70-80 crore, including laboratory infrastructure, pilot lines, analytics and quality systems.
» Read more about: Welcure Drugs & Pharma plans to invest ₹80 crore in agro pharma research lab »
Read MoreHow is global trade shifting amid the US tariffs war?
American farmers warn of lasting damage as Chinese importers choose cheaper alternatives from other countries like Russia and Brazil.
Also, tariffs risk taking some of the steam out of the US coffee industry.
And Roger Hearing hears why the British horseracing sector could face strike action over proposed betting tax changes.
» Read more about: How is global trade shifting amid the US tariffs war? »
Read MoreTariffs and MFN Policy Power a Broad, Confusing Pharma War
Never before has the pharmaceutical industry had to consider international trade agreements in its daily business. The matter was settled in 1994, until Donald Trump returned to the White House with a blizzard of confusing policy proposals, from tariffs to Most Favored Nation Drug pricing. This has left the industry in a collective state of confusion.
» Read more about: Tariffs and MFN Policy Power a Broad, Confusing Pharma War »
Read More1 Science Powerhouse To Own for the Next Decade
Thermo Fisher Scientific has a knack for thriving even in challenging markets. While the company isn’t entirely immune to today’s global headwinds, slower biopharmaceutical spending, tighter budgets in academic labs, and muted demand in China, it has weathered the storm far better than most of its peers.
The reason?
A combination of unmatched scale,
» Read more about: 1 Science Powerhouse To Own for the Next Decade »
Read MoreMix of Bullish Forces Boosted Broadcom (AVGO) in Q2
Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!
AI is eating the world—and the machines behind it are ravenous.
Each ChatGPT query, each model update, each robotic breakthrough consumes massive amounts of energy.
» Read more about: Mix of Bullish Forces Boosted Broadcom (AVGO) in Q2 »
Read MoreThe Burst
2 Energy Giants Practically Mint Cash
Unlike upstream drillers who live by the barrel, Energy Transfer and Kinder Morgan quietly rake in stable cash flows by simply moving, storing, and processing hydrocarbons. Their businesses are mostly fee-based, and that makes them unusually resilient, especially in a market that punishes volatility.
Let’s dig into why these two midstream powerhouses are in a class of their own when it comes to cash generation,
» Read more about: 2 Energy Giants Practically Mint Cash »
Read MoreThe Ivy
Could BigBear.ai Stock Really 3x?
BigBear.ai (NYSE: BBAI) has all the buzzwords that investors love these days AI, defense, government contracts but does that make it a great investment?
Some traders are hoping the stock will 3x but as any seasoned investor knows, hope isn’t a strategy. If you’re wondering what it would actually take to get there,
» Read more about: Could BigBear.ai Stock Really 3x? »
Read MoreThe Spotlight
Is Berkshire The #1 Stock to Buy In This Market?
Warren Buffett isn’t just a famous investor, he’s in a league of his own. Over nearly six decades, he’s compounded Berkshire Hathaway’s value at close to 20% annually. If you invested a meagerly $100 and let it grow at that pace for 60 years, you’d end up with over $5.6 million.
Yet despite Berkshire’s trillion-dollar size today,
» Read more about: Is Berkshire The #1 Stock to Buy In This Market? »